INTRODUCTION
P rogrammed cell death 4 (Pdcd4) is a novel tumor sup pressor that inhibits tumorigenesis by interfering with translation initiation. Pdcd4 exerts its translation inhibitory function largely by inhibiting the helicase activity of eIF4A. 1, 2 Consequently, Pdcd4 is predicted to specifically prevent the tran s lation of mRNAs with highly structured 5′UTRs that require unwinding for efficient translation. As a result of its translation inhibitory effects, Pdcd4 inhibits transformation, migration, and invasion in vitro. 35 In mouse models, transgenic overexpression of Pdcd4 was shown to reduce papilloma multiplicity and incidence in the 2stage skin carcinogenesis model, whereas knockdown of Pdcd4 led to higher tumor yields in the same model. 6, 7 Fur thermore, mice nullizygous for Pdcd4 were reported to spontane ously develop lymphoma. 8 There is also increasing evidence for the tumor suppressive function of Pdcd4 in humans, as recent reports indicate that Pdcd4 is lost in various tumor entities. 912 The loss of Pdcd4 has been shown to be a prognostic marker for colon cancer progression. 13 Mutational inactivation has been excluded as an underlying mechanism for the loss of Pdcd4. 14 Instead, Pdcd4 levels are posttranscriptionally regulated by miR 21 9, 10 and posttranslationally regulated by proteasomal degra dation. 7, 15 The increased proteasomal degradation leading to a reduced protein halflife in response to tumorpromoting condi tions is regulated by p70 S6K1 and/or Aktdependent phosphoryla tion of serine 67. Upon phosphorylation, the E3ubiquitin ligase bTrCP1 binds to and facilitates the ubiquitylation of Pdcd4, thus targeting Pdcd4 for proteasomal degradation. 7, 15 Pdcd4 is also phosphorylated at serine 457 by PKB/Akt, which appears to influence its subcellular localization rather than its stability. 16 Because Pdcd4 appears to be influenced by multiple signaling pathways, it may serve as an important integration point to con trol translational changes during tumorigenesis. Thus, stabilizing Pdcd4 might prove to be an interesting, novel target for interfer ing with dysregulated translation during tumor development.
The therapeutic potential for interfering with translation in cancer treatment is supported by the fact that translation inhibitors have been recognized as promising therapeutic enti ties in tumor therapy in recent years. Rapamycin and its analogs are currently in clinical trials or already approved for use as potent anticancer drugs. These compounds inhibit mTOR (mam malian target of rapamycin), a protein serine/threonine kinase central to the phosphoinositide 3kinase (PI3K) pathway in con trolling gene expression and cell proliferation, and it has been implicated in tumorigenesis. Inhibition of mTOR prevents acti vation of both p70 S6K1 and eIF4E, resulting in inhibition of translation initiation. 17, 18 A recently described smallmolecule inhibitor of eIF4E was also shown to have proapoptotic activity in multiple cancer cell lines. 19 Because mTOR and eIF4E inhibitors target rather general processes, both are predicted to lack specificity. In the case of mTOR inhibitors, immunosup pressive side effects have been a major drawback during their development as anticancer drugs. In fact, rapamycin was ini tially characterized and is still widely used as an immunosup pressant during organ transplants. 18, 20 Similarly, eIF4E inhibitors can be anticipated to generally inhibit capdependent transla tion. Limiting the translation inhibitory effects to a welldefined, tumorrelevant set of target mRNAs would be a more desir able approach. Because Pdcd4 inhibits eIF4A activity, it is predicted to specifically affect translation of socalled weak mRNAs, which are characteristic regulators of many proto oncogenes (e.g., cmyc). 21 Thus, stabilizers of Pdcd4 might prove to be specific in inhibiting tumorassociated changes in translation.
In this report, we describe the development, optimization, and validation of a novel, cellbased highthroughput screening (HTS) assay for the identification of stabilizers of tumor sup pressor Pdcd4. Because this assay measures an increase in signal compared to TPA control, toxic compounds will not be identified as false positives. An offtarget control was developed and used to eliminate nonspecific effects. We further show that the assay robustly and reproducibly identifies predicted Pdcd4 stabilizers from a variety of sources.
MATERIALS AND METHODS

Materials
DMSO, TPA (12OTetradecanoylphorbol13acetate), rapa mycin, LY294002, and antibactin antibody were obtained from Sigma (St. Louis, MO). Antiluciferase antibody and anti rabbit and antimouse horseradish peroxidase (HRP)-coupled antibodies came from Millipore (Billerica, MA). Peptidepurified antiPdcd4 antibody was described previously. 14 Nitrocellulose membranes and enhanced chemiluminescence (ECL) reagents were from Amersham Biosciences (Fairfield, CT). White 384 well plates and Steadylite Plus luciferase reagents were from PerkinElmer (Boston, MA). pGL3control vector was obtained from Promega (Madison, WI) and pFBneo from Stratagene (La Jolla, CA). p70 S6K1 expression plasmids were kindly pro vided by J. Blenis. 22 All media, supplements, and antibiotics for cell culture were purchased from Invitrogen (Carlsbad, CA) unless otherwise noted.
Libraries of pure natural products and synthetic compounds were provided by the Drug Synthesis and Chemistry Branch, Developmental Therapeutics Program, Division of Cancer Treat ment and Diagnosis National Cancer Institute (Frederick, MD). Natural product extracts were obtained from the Natural Pro ducts Support Group, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute (Frederick, MD). A library of known protein kinase inhibitors was obtained from BioMol (Plymouth Meeting, PA). A library of pharmaceutical active compounds (LOPAC1280) was purchased from Sigma. Other synthetic compound libraries were obtained from a variety of commercial and academic sup pliers. Pure compound libraries were stored frozen at 1 to 5 mM in DMSO. Natural product extracts were also stored frozen in DMSO at 1 to 10 mg/mL.
Cloning of Pdcd4-luciferase constructs
Four fragments of Pdcd4 (encoding amino acids 6480, 3991, 16142, 108206) were amplified by PCR using a ran dom human cDNA sample as template. HindIII and NarI res triction sites were added to the Pdcd4specific amplicons. The resulting extended Pdcd4 fragments were fused to the luciferase expression cassette of the pGL3control vector. Subsequently, the Pdcd4luciferase fusion constructs were amplified by PCR, introducing EcoRI and BamHI restriction sides before and after the fusion product, respectively. The resulting Pdcd4luciferase constructs were then inserted into a modified pFBneo plasmid in which the neomycin resistance had been replaced by a blas ticidin resistance cassette. All DNA constructs were confirmed by sequence analysis.
Transfection and transformation
For transient expression, various Pdcd4luc plasmids, TK Renilla luciferase plasmid, and expression plasmids of either mutated (inactive) or wildtype p70 S6K1 were cotransfected into HEK293 cells using Fugene 6 (Roche, Basel, Switzerland) according to the manufacturer's protocol.
For the generation of stable cell lines, Pdcd4luc plasmids and pVSVG packaging plasmid were cotransfected into GP2 293 cells using the same protocol. Packaged virus was col lected using established methods (Clontech, Mountain View, CA). Subsequently, retroviral infection of HEK293 cells was performed to create cells stably expressing either Pdcd4 (16/142) luc, Pdcd4 (39/91) luc, or Pdcd4 (108/206) luc. Clones stably expressing the Pdcd4luc constructs were selected by supplementing regu lar growth medium with 6 mg/mL blasticidin. Expression of the Pdcd4luc constructs was verified using Western blot analysis and luciferase activity measurement after selection for 2 weeks. Monoclonal cell lines were established by singlecell dilutions in 96well plates.
Cell culture conditions and treatment
HEK293 cells were maintained in Dulbecco's modified Eagle medium (DMEM) supplemented with 10% heatinactivated fetal bovine serum (FBS), 100 U/mL penicillin, 100 mg/mL strepto mycin, and 2 mM Lglutamine. Stable HEK293Pdcd4luc cell lines were maintained in regular growth medium supplemented with 3 mg/mL blasticidin. All cells were maintained at 37 °C under 5% CO 2 atmosphere in a humidified incubator.
Cells were trypsinized, concentrated by centrifugation, re s uspended in medium, and added to 384well plates (40 mL/ well) using a mFill microplate liquid dispenser (BioTek, Winooski, VT). Seeding and treatment conditions were optimized as indi cated below. Cells were allowed to attach for 18 h. For screening, 5 mL of 100 nM TPA in medium (containing 1% [v:v] DMSO) was added to each well immediately followed by test samples. "DMSO" control wells received 5 mL of 1% DMSO in medium. Test samples were diluted in medium to 10× final concentration in 384well polypropylene dilution plates (multiple sources) and 5 mL transferred to assay plates containing cells and TPA. Control wells received 5 mL of PBS containing the same DMSO concentration as the diluted samples. Final concentra tions for screening were 5 to 10 mM for pure compounds and 5 mg/mL for natural product extracts. Final DMSO concentra tions were 0.1% to 0.6% (v:v). All dilutions and transfers were performed on a Biomek FX with a 384channel pipet head (Beckman Coulter, Fullerton, CA).
Luminescence measurements
Luminescence measurements were carried out using the Steadylite Plus luciferase reagent from PerkinElmer according the manual. Briefly, 50 mL lysis/detection reagent was added per well (384well plate), and luminescence was measured 10 to 15 min after addition using the PHERAstar luminescence reader (BMG LABTECH, Inc., Durham, NC).
Western blot analysis
For Western blot analysis, cells were sonicated and then lysed on ice for 30 min in lysis buffer (50 mmol/L TrisHCl, 1% NP40, 150 mmol/L NaCl, 1 mmol/L EDTA, 10% glycerol, 1 mmol/L phenylmethylsulphonyl fluoride [PMSF], protease inhibitor mix, phosphatase inhibitor cocktail 2 [Sigma]).
Lysates containing 50 mg protein were separated on sodium dodecyl sulfate (SDS) gels and analyzed using Western blot analysis. Proteins were visualized using specific primary and appropriate secondary antibodies followed by ECL detection.
Data analysis
The activities of compounds were calculated using the fol lowing formula:
Compounds were considered to be hits if the activity-that is, rescue of luciferase signal from TPAinduced reduction rela tive to D DMSOTPA (= RLU DMSO -RLU TPA )-was higher than 50%. For confirmation of activity, primary hits were reassayed in quadruplicate. Hits were considered to be confirmed if the activity remained >50% at a confidence interval of 95%.
For estimation of the reliability of the assay, Z′ values were calculated for each plate comparing DMSO and TPA (10 nM) controls (8 wells each). 23 A Z′ value >0.4 was chosen as the cutoff in the highthroughput screen.
For exclusion of nonspecific effects, primary hits were tested in the offtarget cell line in quadruplicate as well. Because TPA treatment generally did not yield changes relative to DMSO treatment, effects were calculated relative to TPAonly treat ment according to the following formula:
Compounds yielding significant increases (>120%) in the offtarget cells were considered to be nonspecific. Coefficients of variation were used to determine repeatability and reproduc ibility of the assay. Primary hits that were not confirmed in retesting were considered false positives.
Apparent IC 50 values were calculated using SigmaPlot (SPSS, Inc., Chicago) 4parameter logistic nonlinear regres sion analysis. Each assay plate was assessed separately. Unless otherwise noted, all data are presented as mean ± standard deviation.
RESULTS
Generation and validation of reporter constructs and cell lines
For the identification of Pdcd4 stabilizing compounds, fragments of Pdcd4 that span the phosphorylationdependent degradation (PDD) domain containing both the p70 S6K1 phos phorylation and the bTrCP1recognition motifs ( Fig. 1A) were fused to a luciferaseencoding reporter construct (pGL3 control). Specifically, fragments coding for aa 6480, aa 3991, and aa 16142 were used as target constructs, whereas a frag ment coding for adjacent aa 108206 was used as offtarget construct (i.e., the resulting construct does not contain any part of the PDDdomain; Fig. 1B) . Transient coexpression of the resulting reporter vectors with wildtype p70 S6K1 yielded a red uction of the luciferase signal relative to cotransfection with an inactive mutant p70 S6K1 to 25% and 33% for Pdcd4 (16/142) luc and Pdcd4 (39/91) luc, respectively. Pdcd4 (64/80) luc (86%) and Pdcd4 (108/206) luc (111%) did not respond to overexpression of wildtype p70 S6K1 ( Fig. 2A) .
For further experiments, Pdcd4 (16/142) luc and Pdcd4 (39/91) luc were chosen as target and Pdcd4 (108/206) luc as offtarget con structs. Stable HEK293 cell lines were generated expressing either of these 3 constructs. The 2 clones of each construct with the highest luciferase expression were selected for further analysis (Fig. 2B, black arrows) . Pdcd4 (16/142) luc cell lines (clone 5: 53%; clone 8: 54%) and Pdcd4 (39/91) luc cell lines (clone 1: 42%; clone 8: 42%) displayed a strongly decreased luciferase signal in response to 8h TPA (10nM) treatment. The Pdcd4 (108/206) luc cell lines (clone 2: 79%; clone 7: 91%) were only mildly affected by TPA (Fig. 2C) .
In summary, Pdcd4 (39/91) luc was chosen as a sensitive Pdcd4 stability monitoring tool, and Pdcd4 (108/206) luc proved to be a valid specificity control. In all further experiments, Pdcd4 (39/91) luc (clone 8) and Pdcd4 (108/206) luc (clone 2) cell lines were used.
Assay optimization
After initial characterization of constructs and cell lines, optimization of the assay focused on identification of conditions to maximize the difference in signal between DMSO and TPA controls and to provide a robust (high Z′) HTScompatible 384 well assay. Systematic variation of cell numbers only minimally affected the TPAinduced loss of luciferase signal. Thus, opti mal cell number determined by the highest Z′ value was 1000 cells/well (Z′ = 0.70; Fig. 3A) . Varying the concentration of TPA revealed that maximal reduction was achieved at 10 nM (56.2% of DMSO; Z′ = 0.68; Fig. 3B ). The TPA effect was maximal at an 8h incubation as was Z′ calculated for the differ ence between DMSO and TPA (Fig. 3C) . The slightly less pro nounced effect at 4 and 6 h is consistent with previous observations for endogenous Pdcd4, where maximal Pdcd4 down regulation was shown at TPA exposure ≥8 h. 7 For control purposes, the PI3K inhibitor LY294002 and the mTOR inhibitor rapamycin were tested as potential Pdcd4 sta bilizers based on their reported effectiveness in stabilizing Pdcd4. 7 The TPAinduced decrease in Pdcd4 (39/91) luciferase sig nal was attenuated by coincubation with LY294002 or rapamy cin (Fig. 4A) . Treatment of cells with 10 nM TPA resulted in a similar loss of both endogenous Pdcd4 and the luciferase target fusion protein (Fig. 4B) . Treatment with rapamycin (100 nM) or LY294002 (10 mM) completely rescued both proteins. In con trast, luciferase fused to the offtarget construct remained stable and was unaffected by the inhibitors (Fig. 4B) . Doseresponse analysis for LY294002 and rapamycin using the screening assay yielded IC 50 s of <0.1 nM and 2 mM, respectively (Fig. 4C) . Based on its higher efficiency, rapamycin was chosen as the recovery control on each plate. Varying the addition of positive controls between 2h pre and 2h postTPA addition did not change the recovery of the luciferase signal (data not shown). Thus, rapamy cin as well as the test compounds were added within 15 min after TPA addition during the HTS. DMSO concentrations up to 0.7% had no effect on the assay (data not shown). Systematic variation of assay parameters thus confirmed optimal conditions for cell number (1000 cells/well), TPA con centration (10 nM), and incubation time (8 h) . Other variables such as read time, time, and order of addition had minimal effect on the assay.
Assay reproducibility
To evaluate the reproducibility of the assay in an HTSformat, we screened 4 plates containing 1280 compounds of the com mercially available LOPAC1280 (Library of Pharmacolo gically Active Compounds, Sigma) at 10 mM under optimal assay conditions on 3 days in triplicate each day. Figure 5 shows the relative activities (normalized to D DMSO/TPA ) of 2 runs on 2 different days. The resulting slope of the curve was 0.86, and the correlation coefficient was 0.75. Variability for controls (DMSO, TPA, TPA + rapamycin) from plate to plate (coefficients of variation [CVs] 6.4%8.1%), from day to day (CVs 4.9%7.5%), and within a plate (CVs 7.0%7.7%) was low. Platetoplate and daytoday variability (summarized in Table 1 ) was higher for the compounds in the LOPAC1280 library (CVs 10.8% and 17.2%) and for 2111 randomly selected crude natural product extracts (CVs 6.9% and 17.3%).
These observations and an average Z′ value of 0.58 across 446 plates run under screening conditions demonstrate that the assay is highly reliable, reproducible, and well suited for HTS purposes. 
HTS of pure compound and natural product extract libraries
After confirmation of the performance of the assay, various libraries containing a total of 15,275 pure natural and synthetic compounds were screened at 5 or 10 mM. Fortyseven con firmed hits were identified. One of these was shown to be non specific because it showed activity of 134.1% ± 5.4% in the offtarget cell line. Thus, the final hit rate was 0.30% for con firmed, specific hits. Table 2 includes activities of several con firmed hits and depicts likely mechanisms of action for their activity as Pdcd4 stabilizers. Among the hits are mTOR inhibi tors (rapamycin and analogs 18 ), general protein kinase inhibitors (7hydroxystaurosporine, 24 H89, PP1 25 ), inhibitors of PKC sig naling (GF109203X 26 ), ERK inhibitors (hypothemycin 27 ), and previously described antagonists of phorbol ester activity (bryo statin 4 28 ). In addition to pure compounds, 135,678 natural prod uct extracts were analyzed. For these samples, 43 were confirmed by reassay. One of these was eliminated based on activity in the offtarget cell line. Active samples included both organic and aqueous extracts from marine organisms, fungi, and plants.
Thus, the assay appears well suited for HTS of both pure compounds and complex, natural product extracts to reliably identify specific Pdcd4 stabilizers.
DISCUSSION
Expression of a fusion protein of a Pdcd4 fragment and lucif erase (Pdcd4 (39/91) luc; Fig. 1 ) was used to develop an HTS assay for inhibition of TPAinduced Pdcd4 turnover. The assay has proven to be robust and reproducible with regard to cell number, TPA concentration, and incubation times (Fig. 3) . TPA treatment significantly and reproducibly reduced the luciferase signal (Z′ averaged >0.5 throughout screening). Inhibitors of pathways leading to Pdcd4 degradation caused the signal to increase, albeit not to the level of untreated (DMSO) control cells. Application of the assay to libraries of pure natural products and synthetic compounds and to libraries of natural product extracts confirmed reproducibility of results with "real" samples. Table 1 , the CVs of all controls (DMSO, TPA, rapamycin + TPA) were within a range from 4.7% to 8.1% for daytoday, platetoplate, and withinplate repeatability, con firming the robustness of the assay. The CVs for the LOPAC 1280 and the 2111 natural extracts were higher than those of the controls, reflecting an increased variability that may also result from necessary dilution steps when screening libraries. The daytoday variability was consistent and independent of the library source and was higher than the platetoplate vari ability within a single day.
As shown in
As a result of these observations, each plate was treated as an independent experiment. Decisions regarding identification of active samples were made based on controls in the same plate.
Previous work with Pdcd4 suggests that activation of PI3K/ mTOR/p70 S6K1 and MEK/ERK signaling results in destabili zation of Pdcd4. 7, 15 During assay development, 2 inhibitors that target the PI3K/mTOR pathway were used for validation of the assay. The inhibitors were rapamycin (mTOR inhibitor) and LY294002 (PI3 kinase inhibitor). The IC 50 values (estimated from data in Fig. 4C ) for rapamycin (<0.1 nM) and LY294002 (~2 mM) are consistent with expected activities. Rapamycin was chosen as a positive control for the screening assay because it consistently gave a more complete recovery of activity at lower doses compared to LY294002. In addition to these compounds, a number of known, wellcharacterized compounds represented in the compound libraries were identified and confirmed as hits in the screening assay. Table 2 summarizes the activity data for several compounds and the target(s) likely to be involved in Pdcd4 stabilization. It should be noted that many protein kinase inhibitors once thought to be relatively specific in fact have fairly broad inhibitory activity. 25 For example, PP1, iden tified by many suppliers as an src family kinase inhibitor, also inhibits other protein kinases, including p70 S6K1 and ERKs. 25 It is therefore not surprising to see PP1 as a Pcdc4 stabilizer. Although the hit compounds listed in Table 2 would be pre dicted to stabilize Pdcd4 in this assay, detection of these com pounds alone does not validate the assay. However, these results demonstrate that the assay is capable of detecting modu lators of multiple signaling pathways reported to be associated with Pdcd4 stability. Interestingly, a recently described AP1 inhibitor, bryostatin 4, 29 was identified as stabilizing Pdcd4. Pdcd4 has been characterized previously to inhibit AP1 activ ity, 3 and thus bryostatin 4 might exert its AP1 inhibitory func tion by stabilizing Pdcd4. A possible limitation of the assay is that toxic compounds will not be detected even if they might stabilize Pdcd4 at sub toxic concentrations. For example, the general kinase inhibitor staurosporine, which was represented in the tested libraries, would have been predicted to be active, especially in light of the activity identified for 7hydroxystaurosporine. However, the activity of staurosporine (31% ± 12%) remained below the hit threshold. Staurosporine also reduced the luciferase signal in the offtarget cells to 62% ± 4%, indicative of mild toxicity and/or inhibition of protein expression. Similarly, other com pounds potentially stabilizing Pdcd4 might appear as false negatives due to significant cytotoxicity under the assay con ditions. This is further corroborated by screening results of natural product extracts. Of >135,000 extracts tested, only 42 were confirmed to be active and specific. Many natural product extracts have previously shown significant levels of cytotoxic ity in a similar assay. 30 A series of assays to determine the activity of the PI3K/Akt/ mTOR pathway has recently been developed and published. 29 As a measure of mTOR activity, Carlson et al. 31 included an assay that measures phosphorylation of Pdcd4 at Ser457, supposedly by p70 S6K . Ser457 phosphorylation was recently reported to control Pdcd4 localization. 16 Although that assay provides a useful tool for identification of inhibitors of the PI3K/Akt/mTOR pathway, our system is designed to identify compounds affecting Pdcd4. As noted above, Pdcd4 stability is dependent on phosphorylation of a different site, Ser67, 7, 15 which is targeted in this assay. In addition to identifying inhibi tors of PI3K/Akt/mTOR signaling, the assay presented here is predicted to detect modulators of other regulators of Pdcd4 degradation, including ubiquitylation and proteasomal degrada tion. Furthermore, in focusing on the phosphorylation site directly involved in mediating degradation of Pdcd4, we expect to identify modulators of sitespecific phosphorylation events contributing to Pdcd4 destabilization. This approach will require subsequent secondary assays to stratify hits according to their mechanisms of action. One approach to the investigation of mechanism(s) of action of hits visàvis proteasomal degrada tion would be development of an alternative luciferase fusion construct with a different protein that uses the same protea somal degradation pathway as Pdcd4. As a side note, although Carlson et al. 31 used insulin and insulinlike growth factor (IGF) as activators to address feedback signaling events within the PI3K/Akt/mTOR pathway, we focused on tumorpromoting conditions to identify compounds that could be useful as future tumor therapeutics targeting Pdcd4 stability to inhibit tumori genesis. The 2 assays thus have different, albeit potentially complementary, purposes.
Natural product extracts comprise complex mixtures of com pounds, so they can provide significant challenges to screen ing assays. Nevertheless, natural products and derivatives have been and continue to be important sources of novel therapeu tics, 29, 32 including the majority of current cancer chemothera peutics. 32 The ability of this screen to identify active natural product extracts from a variety of taxonomic groups provides access to wide chemical diversity and can be expected to yield novel compounds and, possibly, novel mechanisms of action. The process of extract fractionation is being initiated. As far as we are aware, this is the first systematic, highthroughput investigation of natural product extracts for modulators of Pdcd4 stability.
In addition to detecting known compounds with well characterized mechanisms of action, 37 other compounds were identified. For some of these, interesting biological activities have been reported, including possible antitumor activities. Fur ther investigation will focus on characterizing the mechanisms of action for these compounds and on the purification and char acterization of novel natural products that affect Pdcd4 stabil ity. Compounds identified from this screen will be useful for probing Pdcd4 function and regulation as well as providing starting points for potential therapeutic intervention.
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